1. The roles of pathology in targeted therapy of women with gynecologic cancers 
Rajmohan Murali, Rachel N. Grisham, Robert A. Soslow 
Gynecologic Oncology 
Volume 148, Issue 1, Pages (January 2018)
DOI: /j.ygyno
Copyright © 2017 Elsevier Inc. Terms and Conditions

2. Fig. 1
An overview of the roles of pathology in the management of women with gynecologic cancer.
Gynecologic Oncology  , DOI: ( /j.ygyno )
Copyright © 2017 Elsevier Inc. Terms and Conditions

3. Fig. 2
Pathologic correlates of molecular/genetic alterations in gynecologic cancers. a) Mismatch repair deficient endometrial carcinoma exhibiting low-grade endometrioid histology, tumor-infiltrating lymphocytes (lymphocytes infiltrating neoplastic epithelium) and peritumoral lymphocytes (lymphocytes present adjacent to tumor). b) POLE-mutated endometrial carcinoma showing conspicuous tumor-infiltrating lymphocytes and peri-tumoral lymphocytes and bizarre/giant tumor cell nuclei.
Gynecologic Oncology  , DOI: ( /j.ygyno )
Copyright © 2017 Elsevier Inc. Terms and Conditions

4. Fig. 3
Pathologic correlates of molecular/genetic alterations. a) Homologous recombination-deficient high-grade serous carcinoma exhibiting solid architecture. b) Endometrioid adenocarcinoma with mucinous differentiation, which is more frequently associated with KRAS mutations. c-d) BRAF-mutated serous borderline tumor showing a subpopulation of cells with abundant eosinophilic (pink) cytoplasm (c). Cells bud from the epithelial surface, leading to the appearance of individual cells and clusters of detached cells (c). Immunohistochemistry for BRAF VE1 shows overexpression, which correlates with the presence of V600E BRAF mutation (d).
Gynecologic Oncology  , DOI: ( /j.ygyno )
Copyright © 2017 Elsevier Inc. Terms and Conditions